The disorders discussed in the review include leukodystrophies and genetically determined leukoencephalopathies, a broad collection of rare neurological diseases defined by abnormalities in the brain’s white matter. On magnetic resonance imaging, affected tissue may appear unusually bright, damaged or reduced in volume. Clinically, patients can experience developmental delay, movement abnormalities, seizures, cognitive decline, vision problems or progressive loss of motor function. Despite these shared radiological features, the underlying causes are remarkably diverse, ranging from defects in transcription to failures in RNA maturation or protein production.

Transcription is the first step in converting genetic information into biological function. During this process, DNA sequences are copied into messenger RNA, which carries instructions to the cellular machinery that produces proteins. Mutations in genes controlling transcription can alter which genes are switched on or off, when they are activated and how strongly they are expressed. In the developing and mature nervous system, even modest disturbances in this regulatory network can have far-reaching consequences, particularly in cells that must maintain elaborate structures over many decades.

RNA processing introduces another layer of vulnerability. Newly formed RNA molecules must be edited, spliced and transported before they can serve as accurate templates for protein synthesis. Errors in these steps can produce abnormal or incomplete proteins, reduce the availability of essential transcripts or disrupt the balance between different protein variants. Because neurons and glial cells rely on precisely coordinated gene expression, defective RNA processing may interfere with axonal maintenance, cellular energy management, myelin formation or responses to injury.

Translation, the final stage of the pathway, converts RNA instructions into proteins at the ribosome. Pathogenic variants affecting translation factors, ribosomal components or related quality-control systems can impair the production of proteins throughout the cell. The consequences may be especially severe in the central nervous system, where neurons have extraordinary demands for energy and protein renewal, while oligodendrocytes must generate and maintain large quantities of myelin. A disturbance in protein biosynthesis can therefore undermine both the cells that transmit signals and the cells that insulate them.

One of the most intriguing features of these disorders is their selective neurological impact. The molecular machinery affected by many of the mutations is present in nearly every cell, yet the symptoms often center on the brain and spinal cord. The review highlights this unresolved question as a central theme in the field. Several factors may contribute, including the long lifespan of neurons, the complexity of their connections, the dependence of white matter on specialized glial cells and the unusually high metabolic cost of maintaining myelin. Tissue-specific gene regulation and differences in cellular stress responses may also determine why a broadly expressed defect produces a predominantly neurological disease.

The clinical and radiological diversity of these conditions makes diagnosis particularly challenging. Some patients develop symptoms during infancy or childhood, while others remain well until adolescence or adulthood. White matter changes may be widespread, confined to specific regions or accompanied by abnormalities in the cerebellum, brainstem, spinal cord or peripheral nerves. In certain disorders, imaging patterns can offer an important diagnostic clue; in others, the findings overlap with those of unrelated genetic, inflammatory or metabolic diseases. Integrating clinical history, MRI features, biochemical testing and genomic analysis has therefore become essential.

The review also points to a broader shift in how researchers understand hereditary white matter disease. Rather than viewing each leukodystrophy as an isolated disorder, scientists are beginning to identify shared molecular themes. Defects in transcription, RNA processing and translation can converge on common biological outcomes, including impaired myelin maintenance, cellular stress, disrupted organelle function and altered communication between neurons and glial cells. This convergence may help explain why mutations in very different genes can produce similar patterns of white matter injury and could reveal treatment strategies that apply across multiple diagnoses.

Therapeutic development remains challenging, but the expanding molecular framework is creating new opportunities. Genetic therapies may eventually replace, silence or correct harmful variants in selected conditions. RNA-based approaches could restore normal splicing, stabilize defective transcripts or adjust gene expression. Small molecules might improve protein production, reduce cellular stress or compensate for downstream metabolic disturbances. Supportive care, rehabilitation and early management of seizures or movement disorders remain important, but the long-term goal is to intervene before irreversible loss of myelin and neural tissue occurs.

By placing transcription, RNA processing and translation at the center of white matter biology, the review emphasizes that these diseases are not simply disorders of myelin. They are also disorders of information flow: the failure to accurately copy genetic instructions, prepare them for use or translate them into the proteins required by brain cells. Understanding how these fundamental errors produce selective damage to the nervous system could transform diagnosis and treatment. As genomic technologies identify more disease-causing variants, the challenge will be to connect each mutation to its molecular consequences—and to turn that knowledge into therapies for patients whose conditions have long remained unexplained.

Subject of Research: Hereditary white matter disorders caused by defects in transcription, RNA processing and translation

Article Title: White matter disorders at the intersection of transcription, RNA processing and translation

Article References: Chapleau, A., Villa Tobón, F. & Bernard, G. “White matter disorders at the intersection of transcription, RNA processing and translation.” Nature Reviews Neurology (2026). https://doi.org/10.1038/s41582-026-01248-1

Image Credits: AI Generated

DOI: 10.1038/s41582-026-01248-1

Keywords: leukodystrophies, hereditary white matter disorders, leukoencephalopathies, transcription, RNA processing, translation, protein biosynthesis, myelin, neurogenetics, central nervous system

TDP-43, a DNA/RNA-binding protein, has long been recognized for its pivotal role in RNA metabolism, including splicing, transport, and stability. In both FTD and ALS, pathological aggregation and mislocalization of TDP-43 occur, marked by its nuclear clearance and cytoplasmic accumulation in neurons. The current study delves deep into the consequences of TDP-43 loss from the nucleus, focusing specifically on how this loss rewires RNA processing mechanisms at the level of polyadenylation site choice.

Alternative polyadenylation is a critical post-transcriptional regulatory mechanism that determines the length and composition of the 3’ untranslated regions (3’ UTRs) of mRNAs. By selecting different polyadenylation sites, cells can modulate mRNA stability, localization, and translation efficiency. Importantly, dysregulation of APA has been implicated in cancer and other diseases but had remained relatively unexplored in neurodegeneration until now.

Utilizing state-of-the-art transcriptome-wide analyses and high-throughput sequencing of poly(A) sites, the research team charted the APA landscape in neuronal cells subjected to nuclear TDP-43 depletion. Their data revealed an extensive rewiring of polyadenylation patterns, with a significant propensity toward usage of distal poly(A) sites, thereby producing mRNAs with elongated 3’ UTRs. Such elongation is known to introduce additional regulatory motifs, including microRNA binding sites and RNA-binding protein interaction domains, which can alter post-transcriptional gene regulation dramatically.

One of the most striking aspects of the findings was the observation that the genes affected by APA changes due to TDP-43 loss are predominantly involved in synaptic function, neuronal projection, and inflammation—pathways heavily implicated in FTD/ALS pathology. This suggests that TDP-43’s role in maintaining APA homeostasis is instrumental to neuronal health and that its perturbation contributes directly to the neurodegenerative cascade.

Furthermore, the study illuminated potential feedback loops by which APA alterations themselves affect RNA-binding proteins, including those interacting with TDP-43. This network effect could amplify RNA misprocessing and exacerbate disease progression. These insights provide a nuanced framework to understand how molecular dysfunction translates into cellular vulnerability and widespread neurodegeneration.

Intriguingly, the investigation extended to patient-derived tissues, where the APA signatures observed in vitro were recapitulated in FTD and ALS brain samples. This concordance underscores the clinical relevance of TDP-43-mediated APA dysregulation and highlights its potential utility as a biomarker for disease diagnosis or progression monitoring.

The mechanistic insights gleaned from this work underscore the versatility of TDP-43 as a guardian of RNA integrity. Beyond its known role in splicing repression, TDP-43 appears integral to the orchestration of alternative polyadenylation machinery. The depletion of nuclear TDP-43 seemingly dismantles this regulatory scaffold, skewing polyadenylation landscapes toward pathogenic states.

In addition to molecular characterization, the authors embarked on probing whether restoration of TDP-43 nuclear localization or direct modulation of APA patterns could ameliorate pathogenic phenotypes. Preliminary interventions in cellular models hint that correcting APA imbalances can partially rescue neuronal dysfunction, spotlighting novel therapeutic strategies that may complement existing anti-aggregation approaches.

Another fascinating dimension of this research is the potential crosstalk between TDP-43 loss and other RNA processing disruptions observed in FTD/ALS, such as splicing abnormalities and altered RNA stability. The integration of these RNA-centric defects possibly contributes to the heterogeneity and complexity that characterizes these neurodegenerative disorders.

Technologically, the study employed innovative long-read sequencing combined with 3’ end RNA sequencing to precisely map polyadenylation sites and quantify isoform abundance. This methodological advance provided unprecedented resolution to capture the nuanced changes instigated by TDP-43 loss, setting a new standard for future explorations of post-transcriptional regulation in neurological disease contexts.

Beyond basic science, these findings bear implications for therapeutic development pipelines. Targeting APA dysregulation could herald a new class of RNA-based interventions, such as antisense oligonucleotides or small molecules that modulate cleavage and polyadenylation specificity. With neurodegenerative disorders notoriously difficult to treat, any leverage point on the RNA processing axis is invaluable.

Critically, this research also prompts a reevaluation of the pathological roles of RNA-binding proteins beyond their classical functions. TDP-43’s multifaceted involvement in RNA metabolism expands our conceptual framework and suggests that combinatorial targeting of RNA pathways might be necessary for effective disease modification.

The study’s contributions extend toward a holistic understanding of the RNA regulatory network’s fragility in neurodegeneration. It demonstrates that nuclear proteins like TDP-43 act not only as static guardians but as dynamic modulators of RNA fate, whose disruption cascades through cellular systems, amplifying damage.

Echoing the growing appreciation of RNA biology’s centrality in neurodegenerative disease, this work establishes alternative polyadenylation as a pivotal node affected by TDP-43 pathology. It offers fresh perspectives and a robust dataset that will fuel future inquiries aiming to untangle the complex molecular pathogenesis of FTD and ALS.

In sum, the identification of widespread APA changes induced by TDP-43 nuclear loss reshapes our understanding of the molecular underpinnings driving FTD and ALS. While many challenges remain, including translation to therapies and in vivo validation, this study charts an exciting trajectory for neurodegeneration research centered on RNA dynamics.

As the scientific community presses onward, these insights highlight the profound ripple effect a single protein’s nuclear mislocalization can impart, influencing RNA landscapes and neuronal health. This research not only deepens our molecular understanding but also energizes the search for innovative, RNA-targeted treatments that may ultimately alleviate the burden of devastating neurodegenerative conditions.

Subject of Research: The molecular consequences of TDP-43 nuclear loss on alternative polyadenylation patterns in frontotemporal dementia and amyotrophic lateral sclerosis.

Article Title: TDP-43 nuclear loss in FTD/ALS causes widespread alternative polyadenylation changes.

Article References:
Zeng, Y., Lovchykova, A., Akiyama, T. et al. TDP-43 nuclear loss in FTD/ALS causes widespread alternative polyadenylation changes. Nat Neurosci (2025). https://doi.org/10.1038/s41593-025-02049-3

Image Credits: AI Generated